PierianDx acquires Tute Genomics
Clinical genomic company PierianDx is acquiring Tute Genomics, a software company based in Provo, Utah, as part of its goal to expand and improve its business.
PierianDx specializes in creating cloud-based software for personalized medicine for clinical labs. They aim to treat somatic cancer with the addition of Tute by using their exome testing technology, the company said in a statement. By combining operations, they will provide a single clinical platform for clinical workflow support.
“We are excited to welcome Tute Genomics customers and employees to the PierianDx team,” said PierianDx CEO Ted Briscoe in a statement. “The enhanced platform will provide labs with a single clinical solution to support a comprehensive range of molecular testing for personalized medicine.”
As part of the acquisition, Tute CEO Reid Robison will join PierianDx’s board of directors. Tute COO Andy Olson and Vice President of Product Development Bryce Daines will relocate to PierianDx’s offices in St. Louis.
“PierianDx is a leader in enabling precision medicine and I am confident that this partnership will significantly accelerate our shared vision of bringing genomics and personalized medicine into everyday healthcare,” Robison said.
In December 2015, Tute acquired the assets of Knome, a human-genome interpretation company.
Senior Writer
As a Senior Writer for TriMed Media Group, Katherine primarily focuses on producing news stories, Q&As and features for Cardiovascular Business. She reports on several facets of the cardiology industry, including emerging technology, new clinical trials and findings, and quality initiatives among providers. She is based out of TriMed's Chicago office and holds a bachelor's degree in journalism from Columbia College Chicago. Her work has appeared in Modern Healthcare, Crain's Chicago Business and The Detroit News. She joined TriMed in 2016.